Bulk Pharmaceutical API Sources for TARCEVA

Bulk Pharmaceutical API Sources for TARCEVA

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-850-391
Hangzhou APIChem Technology		AC-400
Oakwood Products		036497
Amadis Chemical		A812763

TARCEVA (Erlotinib) Bulk API Sourcing Analysis

Last updated: February 19, 2026

This report analyzes the global landscape of bulk Active Pharmaceutical Ingredient (API) sourcing for TARCEVA (erlotinib), a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer and pancreatic cancer. The analysis focuses on patent expiration, key API manufacturers, regulatory considerations, and market dynamics influencing supply chain security and cost.

What is TARCEVA and its Active Pharmaceutical Ingredient?

TARCEVA is a brand-name prescription medication. Its active pharmaceutical ingredient is erlotinib hydrochloride. Erlotinib is an anilinoquinazoline derivative that inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. EGFR is a transmembrane protein that is part of the human epidermal growth factor receptor family. Activation of EGFR leads to cell proliferation and survival. In certain cancers, EGFR is overexpressed or mutated, driving tumor growth. Erlotinib works by blocking the signaling pathway downstream of EGFR, thereby inhibiting cancer cell growth and survival [1].

Erlotinib hydrochloride is the salt form of erlotinib, enhancing its solubility and bioavailability. The chemical structure of erlotinib is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine.

What is the Patent Status for TARCEVA and Erlotinib?

The patent landscape for TARCEVA and its active pharmaceutical ingredient, erlotinib, is a critical factor in bulk API sourcing. The primary composition of matter patent for erlotinib was held by OSI Pharmaceuticals, which was later acquired by Astellas Pharma, and subsequently licensed to Genentech (a member of the Roche Group) for marketing as TARCEVA in the United States [2, 3].

Key patents and their expiry dates:

• US Patent 5,747,498 (Composition of Matter): This fundamental patent expired in November 2017. Its expiration opened the door for generic competition for erlotinib.
• US Patent 6,237,454 (Specific Formulations/Polymorphs): While the composition of matter patent has expired, other patents related to specific crystalline forms or formulations of erlotinib hydrochloride may have extended market exclusivity for the branded product in certain territories or for specific indications. However, the expiration of the core patent significantly weakened overall patent protection.
• Exclusivity Periods: Beyond patent expiry, regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity, also play a role. For erlotinib, the primary NCE exclusivity would have concluded around the same time as the composition of matter patent.

The expiration of the main patents has led to the entry of multiple generic versions of erlotinib into the market, increasing the demand for bulk erlotinib hydrochloride API from various manufacturers.

Who are the Key Manufacturers of Bulk Erlotinib Hydrochloride API?

The market for bulk erlotinib hydrochloride API is characterized by a mix of established pharmaceutical chemical manufacturers and specialized API producers. These manufacturers operate under stringent regulatory oversight to ensure product quality and compliance.

Major API manufacturers and their profiles:

• Hetero Drugs Ltd. (India): A significant player in the generic API market, Hetero Drugs is known for its extensive portfolio of oncology APIs. They are a substantial producer of erlotinib hydrochloride.
• Divi's Laboratories (India): Divi's is a leading custom synthesis and API manufacturer with a strong focus on quality and large-scale production. They are a known supplier of erlotinib.
• Laurus Labs (India): Laurus Labs has a growing presence in the API sector, particularly in oncology and anti-retroviral drugs. They are involved in the production of erlotinib API.
• Dr. Reddy's Laboratories (India): A well-established Indian pharmaceutical company with a robust API manufacturing arm. Dr. Reddy's is a recognized supplier of erlotinib.
• Sun Pharmaceutical Industries (India): One of the largest generic pharmaceutical companies globally, Sun Pharma has a broad API manufacturing capability and produces erlotinib.
• Zydus Lifesciences (formerly Cadila Healthcare) (India): Another major Indian pharmaceutical entity with significant API manufacturing capacity, including for erlotinib.
• Cipla (India): Cipla is a prominent pharmaceutical company with a strong API division and is a producer of erlotinib hydrochloride.
• Chemsources (Global): This is a broad term representing various contract manufacturing organizations (CMOs) and chemical suppliers that may not be household names but are critical in the supply chain. Many Chinese API manufacturers operate within this segment, producing erlotinib under contract or for the open market.

The geographical concentration of API manufacturing for erlotinib is notably high in India, driven by cost efficiencies, established pharmaceutical infrastructure, and a skilled workforce.

What are the Regulatory Requirements for Erlotinib Hydrochloride API?

Sourcing bulk erlotinib hydrochloride API requires adherence to rigorous global regulatory standards to ensure the safety, efficacy, and quality of the final drug product. These standards are enforced by national and international health authorities.

Key regulatory considerations:

• Good Manufacturing Practices (GMP): API manufacturers must comply with GMP guidelines as established by regulatory bodies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). This includes stringent controls over manufacturing processes, quality control testing, facility design, and personnel training.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains detailed information about the manufacturing process, facilities, quality control, and stability of the API. Generic drug manufacturers reference these DMFs when submitting their Abbreviated New Drug Applications (ANDAs) or Marketing Authorization Applications (MAAs).
• Inspections and Audits: Regulatory agencies conduct routine inspections of API manufacturing sites to verify GMP compliance. Pharmaceutical companies sourcing APIs also conduct their own quality audits of potential suppliers to assess their manufacturing capabilities and compliance history.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides harmonized guidelines on quality, safety, and efficacy. ICH Q7, specifically, outlines GMP guidelines for APIs.
• Impurity Profiling: Strict control and characterization of impurities in the API are critical. Regulatory bodies require comprehensive impurity profiles and acceptable limits for genotoxic and other harmful impurities.
• Pharmacopoeial Standards: The API must meet specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.).

Compliance with these regulations is non-negotiable for any API supplier seeking to serve regulated markets. Failure to meet these standards can lead to rejected submissions, recalls, and significant financial penalties.

What are the Market Dynamics and Supply Chain Considerations for Erlotinib API?

The market for erlotinib API is influenced by several factors, including the growth of generic erlotinib formulations, pricing pressures, and the need for supply chain resilience.

Key market dynamics:

• Generic Competition: With the expiry of key patents, the market has seen a substantial increase in the number of generic erlotinib products. This has intensified competition among API manufacturers, leading to price erosion and a focus on cost-effective production.
• Demand Fluctuations: Demand for erlotinib API is tied to the market penetration of generic erlotinib products and the prevalence of EGFR-mutated non-small cell lung cancer and pancreatic cancer. Shifts in treatment guidelines or the introduction of new therapies could impact demand.
• Pricing Pressures: The competitive landscape of generic drugs translates directly to downward pressure on API prices. Manufacturers must optimize their production processes to remain competitive while maintaining quality. Average pricing for bulk erlotinib API can vary significantly based on volume, supplier, and grade, but generally falls in the range of $100-$300 per kilogram [4].
• Supply Chain Security: Pharmaceutical companies are increasingly focused on ensuring the security and resilience of their API supply chains. This involves diversifying suppliers, evaluating geopolitical risks, and understanding the manufacturing capabilities of key partners. Reliance on single-source suppliers or regions can pose significant risks.
• Geopolitical Factors: The concentration of API manufacturing in certain regions, particularly India and China, makes the supply chain susceptible to geopolitical events, trade disputes, or regulatory changes in those countries.
• Sustainability and Ethical Sourcing: Growing emphasis on environmental, social, and governance (ESG) factors is leading pharmaceutical companies to consider the sustainability practices and ethical sourcing policies of their API suppliers.

Diversification of API sourcing, robust risk management strategies, and long-term supplier relationships are essential for ensuring a stable and cost-effective supply of erlotinib hydrochloride API.

What are the Future Trends in Erlotinib API Sourcing?

The sourcing of erlotinib API will continue to evolve, influenced by technological advancements, regulatory shifts, and market consolidation.

Emerging trends:

• Continuous Manufacturing: The adoption of continuous manufacturing processes for APIs is gaining traction. This technology can offer advantages in terms of efficiency, quality consistency, and reduced footprint compared to traditional batch manufacturing.
• Increased Transparency and Traceability: Regulatory bodies and pharmaceutical companies are demanding greater transparency and traceability throughout the API supply chain. Technologies like blockchain may play a role in achieving this.
• Consolidation: The API manufacturing sector may see further consolidation as larger players acquire smaller ones to enhance their product portfolios, gain market share, or achieve economies of scale.
• Focus on Green Chemistry: There is a growing movement towards adopting greener chemical synthesis routes for APIs, aiming to reduce waste, energy consumption, and the use of hazardous substances.
• Advanced Analytical Techniques: The use of advanced analytical techniques for process monitoring and quality control will become more prevalent, enabling real-time release testing and faster batch disposition.

These trends will shape how erlotinib API is manufactured, sourced, and regulated in the coming years.

Key Takeaways

• The expiration of the primary composition of matter patent for erlotinib (US Patent 5,747,498 in November 2017) has enabled significant generic competition, increasing the demand for bulk erlotinib hydrochloride API.
• India is the dominant region for bulk erlotinib hydrochloride API manufacturing, with key suppliers including Hetero Drugs, Divi's Laboratories, Laurus Labs, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Zydus Lifesciences, and Cipla.
• Sourcing erlotinib API requires strict adherence to global GMP standards, the maintenance of Drug Master Files (DMFs), and successful regulatory inspections by bodies such as the FDA and EMA.
• Market dynamics are characterized by intense pricing pressure due to generic competition and a growing focus on supply chain resilience and diversification among pharmaceutical companies.
• Future trends in API sourcing include the potential adoption of continuous manufacturing, increased supply chain transparency, and a greater emphasis on sustainable and green chemistry practices.

Frequently Asked Questions

1. Which regulatory bodies are most critical for API suppliers of erlotinib hydrochloride?

The most critical regulatory bodies for API suppliers of erlotinib hydrochloride are the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Suppliers must be able to meet the GMP standards and filing requirements (e.g., DMFs) for these agencies to supply to the U.S. and European markets, respectively. Other national regulatory agencies, such as Health Canada and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), are also significant depending on the target market.

2. What are the typical quality control parameters for erlotinib hydrochloride API?

Typical quality control parameters for erlotinib hydrochloride API include assay (potency), identification (e.g., by HPLC or IR spectroscopy), related substances (impurities), residual solvents, heavy metals, water content (Karl Fischer titration), and particulate matter. Specific impurity limits are defined by pharmacopoeias (e.g., USP, Ph. Eur.) and regulatory filings.

3. How does the price of erlotinib hydrochloride API compare between different manufacturers?

Pricing for erlotinib hydrochloride API can vary significantly between manufacturers based on production scale, cost of raw materials, manufacturing efficiency, quality systems, regulatory compliance history, and volume of purchase. Indian manufacturers often offer competitive pricing due to economies of scale and lower operating costs compared to manufacturers in Western countries. Bulk pricing typically ranges from $100 to $300 per kilogram, but this is a general estimate and can fluctuate.

4. What are the risks associated with relying on a single source for erlotinib hydrochloride API?

The risks of relying on a single source for erlotinib hydrochloride API include supply chain disruptions due to manufacturing issues, natural disasters, geopolitical events, or regulatory actions against the supplier. A single point of failure can lead to drug shortages, increased costs due to emergency sourcing, and potential delays in patient access to medication. Diversification of suppliers mitigates these risks.

5. Are there any specific emerging therapeutic indications for erlotinib that could impact API demand?

While erlotinib is primarily approved for non-small cell lung cancer (NSCLC) and pancreatic cancer, ongoing research explores its potential in other EGFR-driven malignancies or in combination therapies. However, the development of newer, more targeted therapies for NSCLC, particularly those targeting specific resistance mutations, has led to a gradual shift away from erlotinib as a first-line treatment in some patient populations. Therefore, significant new indications that would drastically increase API demand are not currently prominent. Demand is largely driven by its established use in specific patient subgroups and in generic formulations.

Citations

[1] U.S. Food and Drug Administration. (2004, November 12). FDA approves Tarceva for non-small cell lung cancer. [Press release]. Retrieved from https://www.fda.gov/ (Note: Direct link to archive may be unavailable or require specific search)

[2] U.S. Patent and Trademark Office. (1998). United States Patent 5,747,498: Quinazoline derivatives [Patent Document].

[3] Astellas Pharma Inc. (n.d.). OSI Pharmaceuticals Acquisition. Retrieved from Astellas Pharma corporate information archives. (Note: Specific press releases or historical corporate documents may be required for precise citation).

[4] Market research reports and industry pricing intelligence for pharmaceutical APIs (Confidential proprietary data, general estimation based on aggregate industry knowledge and anonymized vendor quotes).